Urine Concentration & Dilution

The kidney's ability to vary urine osmolality from ~50 mOsm/kg (maximally dilute) to ~1200 mOsm/kg (maximally concentrated) hinges on a hyperosmotic medullary interstitium and antidiuretic hormone (ADH). This single mechanism underlies the high-yield NEET PG correlations of SIADH versus diabetes insipidus.

Core concept & definitions

The healthy human kidney must excrete a daily solute load (~600 mOsm) in a variable water volume. To conserve water, it produces concentrated urine; to dump excess water, it produces dilute urine. The defining structural prerequisite is a corticomedullary osmotic gradient — cortex isosmotic with plasma (~300 mOsm/kg) rising progressively to ~1200–1400 mOsm/kg at the tip of the inner medulla (papilla).

Key terms:

Term	Meaning	Typical value
Plasma osmolality	Solute concentration of plasma	285–295 mOsm/kg
Maximal urine osmolality	Tip of papilla / max ADH effect	~1200 mOsm/kg
Minimal urine osmolality	No ADH, dilute urine	~50 mOsm/kg
Obligatory water loss	Minimum water to excrete 600 mOsm at max concentration	~0.5 L/day
Free water clearance (C_H2O)	Volume of solute-free water cleared per unit time	+ in water diuresis, − when concentrating

High-yield: Only the loop of Henle (juxtamedullary nephrons) can establish the medullary gradient via the countercurrent multiplier; the collecting duct then uses this gradient (driven by ADH) to concentrate urine. Establishment and utilisation are two separate steps.

Free water clearance: C_H2O = V − C_osm, where V = urine flow rate and C_osm = (U_osm × V)/P_osm. Positive C_H2O means water is being lost in excess of solute (dilution/water diuresis); negative C_H2O means the kidney is reclaiming free water (concentrating).

Segmental handling of the tubular fluid

A stepwise walk of osmolality along the nephron is a favourite MCQ:

Proximal tubule (always isosmotic, 300) → descending thin limb (rises to ~1200 at tip) → ascending limb (falls; fluid becomes hypo-osmotic ~100–150) → early distal tubule (most dilute ~100) → collecting duct (variable: 50 without ADH, up to 1200 with ADH).

Segment	Water permeable?	Solute transport	Fluid osmolality at exit
Proximal tubule	Yes (highly)	Iso-osmotic reabsorption	~300 (isosmotic)
Thin descending limb	Yes	Passive (impermeable to NaCl)	Rises toward 1200
Thin ascending limb	No	Passive NaCl efflux	Falls
Thick ascending limb (TAL)	No	Active NaCl reabsorption (NKCC2)	~150 (dilute)
Early distal tubule	No	NaCl (NCC)	~100 (most dilute point)
Collecting duct	ADH-dependent	Na (ENaC), urea (inner medulla)	50 → 1200

High-yield: The thick ascending limb is the "diluting segment" — it actively pumps out NaCl but is water-impermeable, so tubular fluid leaving it is hypotonic regardless of ADH status. This is why a loop diuretic (frusemide) impairs both concentration and dilution.

The countercurrent multiplier (loop of Henle)

This is the engine that builds the gradient. "Countercurrent" = fluid flows in opposite directions in the two parallel limbs of the hairpin loop; "multiplier" = a small horizontal (transverse) gradient at each level is multiplied vertically into a large longitudinal gradient.

The single effect is the cornerstone: the TAL actively reabsorbs NaCl (via the apical Na⁺-K⁺-2Cl⁻ cotransporter, NKCC2) into the interstitium without water following (TAL is water-impermeable). This makes the interstitium hyperosmotic and tubular fluid hypo-osmotic — a transverse gradient of about 200 mOsm/kg at any horizontal level. Because the descending limb is freely water-permeable, water leaves it to equilibrate with the now-hyperosmotic interstitium, concentrating the fluid inside the descending limb.

Stepwise logic of multiplication:

1. Single effect: TAL pumps NaCl out → interstitium up by ~200, descending limb fluid equilibrates upward by water loss.
2. Flow shifts new isosmotic fluid in from the proximal tubule, displacing concentrated fluid around the bend into the ascending limb.
3. Repeat: the single effect acts again on this already-concentrated fluid.
4. Iterative repetition multiplies the limited 200 mOsm transverse gradient into a ~900–1000 mOsm longitudinal gradient from cortex to papilla.

High-yield: The maximum transverse gradient the TAL can generate at any level is only ~200 mOsm/kg. The huge corticopapillary gradient (~900+ mOsm) is achieved by countercurrent multiplication of this small step, aided by loop length. Long-looped juxtamedullary nephrons (≈15% of nephrons) are essential.

Energy source: the medullary gradient is ultimately powered by active NaCl transport in the TAL, fuelled by the basolateral Na⁺/K⁺-ATPase. ROMK recycles K⁺ back to the lumen to sustain NKCC2; the lumen-positive transepithelial potential drives paracellular reabsorption of Ca²⁺ and Mg²⁺ — explaining hypercalciuria and hypomagnesaemia in Bartter syndrome / with loop diuretics.

Countercurrent exchanger (vasa recta)

A gradient that took energy to build would be quickly washed out by medullary blood flow if the vasa recta were ordinary capillaries. The vasa recta solve this as a passive countercurrent exchanger: they are hairpin loops running parallel to the loops of Henle.

• Descending vasa recta: as blood dips into the hyperosmotic medulla, NaCl and urea diffuse in, water diffuses out — blood osmolality rises toward 1200.
• Ascending vasa recta: returning toward cortex, NaCl/urea diffuse out and water diffuses in — blood re-equilibrates downward.

Net effect: solute that entered on the way down largely leaves on the way up, so the vasa recta carry away reabsorbed water without dissipating the solute gradient. Slow medullary blood flow further protects the gradient.

High-yield: The vasa recta preserve the gradient (passive exchanger); they do not create it. Increased medullary blood flow (e.g. high flow states, certain drugs) causes medullary washout and impaired concentrating ability. Osmotic diuretics and chronic high water intake also wash out the gradient.

Urea recycling

Urea contributes nearly half of the inner-medullary osmolality during antidiuresis. The mechanism:

1. ADH increases water reabsorption in the cortical and outer-medullary collecting duct, which concentrates urea in the tubular fluid (these segments are urea-impermeable).
2. In the inner medullary collecting duct (IMCD), ADH upregulates urea transporters UT-A1 and UT-A3, allowing urea to diffuse down its concentration gradient into the inner-medullary interstitium.
3. This deposited urea raises interstitial osmolality, drawing water out of the descending limb and recycling: some urea re-enters the thin limbs (via UT-A2) and is carried back.

High-yield: Maximal urine concentrating ability is impaired by a low-protein diet (less urea generated) and enhanced by ADH (which boosts UT-A1/A3). Urea recycling is the reason a protein-malnourished or pregnant patient may have a modestly reduced U_osm ceiling.

ADH (vasopressin / AVP) action

ADH (arginine vasopressin) is synthesised in the supraoptic and paraventricular nuclei of the hypothalamus and released from the posterior pituitary. The dominant stimulus is a rise in plasma osmolality sensed by hypothalamic osmoreceptors; non-osmotic stimuli include hypovolaemia/hypotension (baroreceptor-mediated, most potent driver overall), nausea, pain, and drugs.

V2 receptor pathway (concentrating):

ADH binds V2 receptor (basolateral, collecting duct principal cell) → Gs protein → adenylate cyclase → ↑ cAMP → PKA → phosphorylation & insertion of preformed aquaporin-2 (AQP2) vesicles into the apical membrane → water reabsorption. Water exits the cell basolaterally via constitutive AQP3 and AQP4.

Receptor	Location	Coupling	Main effect
V1a	Vascular smooth muscle	Gq → IP₃/Ca²⁺	Vasoconstriction (pressor)
V1b (V3)	Anterior pituitary	Gq	ACTH release
V2	Collecting duct, vascular endothelium	Gs → cAMP	AQP2 insertion (antidiuresis); also vWF/factor VIII release

High-yield: ADH inserts AQP2 apically (the regulated, ADH-sensitive channel) in collecting duct principal cells via the V2 → cAMP pathway. Nephrogenic DI = defective V2 receptor or AQP2; desmopressin (DDAVP) is a selective V2 agonist used in central DI. Chronic ADH also increases total AQP2 transcription.

Disorders of concentration & dilution

This is the clinical payoff and the most-tested correlation. Differentiate using plasma osmolality, urine osmolality, and serum sodium.

Feature	Central DI	Nephrogenic DI	Primary polydipsia	SIADH
Defect	↓ ADH secretion	Renal ADH resistance	Excess water intake	Inappropriate ↑ ADH
Serum Na / P_osm	High–normal/high	High–normal/high	Low–normal/low	Low (hyponatraemia)
Urine osmolality	Low (<300)	Low (<300)	Low	Inappropriately high (>100, often >300)
Urine volume	Polyuria	Polyuria	Polyuria	Normal/low
Response to DDAVP	U_osm rises >50%	No response	(n/a)	—
Volume status	Euvolaemic	Euvolaemic	Euvolaemic	Euvolaemic, no oedema

Water deprivation test → then DDAVP is the classic stepwise diagnostic flow:

1. Deprive water; measure serial urine osmolality and weight.
2. Normal/primary polydipsia: U_osm rises appropriately (>800).
3. DI: U_osm stays low despite rising plasma osmolality.
4. Give DDAVP: U_osm rises >50% → central DI; little/no rise → nephrogenic DI.

High-yield: SIADH = euvolaemic hyponatraemia with inappropriately concentrated urine (U_osm >100), urine Na typically >30–40 mmol/L, low serum uric acid, normal renal/thyroid/adrenal function. Treat with fluid restriction first; add tolvaptan (V2 antagonist) or demeclocycline if refractory; hypertonic saline for severe symptomatic (seizures) hyponatraemia.

High-yield: Correct hyponatraemia slowly — no more than ~8–10 mmol/L in 24 h — to avoid osmotic demyelination syndrome (central pontine myelinolysis). Over-rapid correction of hyponatraemia causes demyelination; over-rapid correction of hypernatraemia causes cerebral oedema.

Causes worth memorising:

• Nephrogenic DI: lithium (classic), hypercalcaemia, hypokalaemia, chronic kidney disease, demeclocycline, congenital V2/AQP2 mutations.
• Central DI: trauma/neurosurgery, pituitary tumours, granulomas (sarcoid, histiocytosis), idiopathic/autoimmune.
• SIADH: small-cell lung carcinoma (ectopic ADH), CNS pathology, pulmonary disease (pneumonia, TB), drugs (carbamazepine, SSRIs, cyclophosphamide, vincristine).

Pathophysiology of impaired concentrating ability

Loss of concentrating ability ("isosthenuria", U_osm fixed ~300) is an early renal sign. Mechanisms map directly to the physiology:

• Loop diuretics (frusemide): block NKCC2 → no single effect → gradient cannot be built → impaired concentration and dilution.
• Medullary washout: osmotic diuresis (mannitol, glucose in DM), high medullary blood flow, prolonged high water intake.
• Low protein: reduced urea contribution to inner medullary osmolality.
• Hypokalaemia / hypercalcaemia: interfere with NKCC2 and AQP2 → acquired nephrogenic DI.
• Ageing / CKD: loss of juxtamedullary nephrons and reduced gradient.

Key differentials & traps

• Polyuria differential: DI (water diuresis, low U_osm) vs osmotic diuresis (high solute excretion, U_osm closer to plasma, e.g. uncontrolled diabetes, post-obstructive). Calculate solute output: >1000 mOsm/day suggests osmotic diuresis.
• Hyponatraemia differential: assess volume status first — hypovolaemic (GI/renal loss), euvolaemic (SIADH, hypothyroid, glucocorticoid deficiency), hypervolaemic (cardiac failure, cirrhosis, nephrotic). SIADH is a diagnosis of exclusion in a euvolaemic patient.
• Cerebral salt wasting vs SIADH: both hyponatraemic with high urine Na, but CSW is hypovolaemic (treat with salt + volume) whereas SIADH is euvolaemic (treat with fluid restriction). A classic NEET PG trap.

Recently asked / exam angle

• Identify the diluting segment (thick ascending limb) and why loop diuretics impair urinary concentration.
• The single effect and the ~200 mOsm transverse gradient that is "multiplied" → numerical/conceptual MCQs.
• AQP2 + V2 + cAMP as the molecular basis of ADH action; AQP3/AQP4 are basolateral and constitutive.
• Water deprivation–DDAVP interpretation to separate central vs nephrogenic DI.
• SIADH lab signature: euvolaemic hyponatraemia, U_osm >100, urine Na high, low serum uric acid.
• Lithium → nephrogenic DI (downregulates AQP2) — repeatedly tested.
• Vasa recta = countercurrent exchanger that preserves, not creates the gradient; medullary washout concept.
• Urea recycling / UT-A1 upregulation by ADH and the effect of a low-protein diet on maximal U_osm.
• Osmotic demyelination from over-rapid correction of hyponatraemia (rate limit ~8 mmol/L/day).
• Site of maximal dilution = early distal tubule (~100 mOsm/kg).

Rapid revision

1. Maximal U_osm ~1200; minimal ~50; plasma 285–295 mOsm/kg.
2. TAL (NKCC2) = diluting segment, water-impermeable → builds gradient and dilutes fluid.
3. Single effect = ~200 mOsm transverse step, multiplied to ~900+ longitudinal gradient.
4. Descending limb: water-permeable, NaCl-impermeable (fluid concentrates); ascending limb: opposite.
5. Vasa recta = passive countercurrent exchanger, preserves gradient; increased flow → medullary washout.
6. Urea contributes ~half of inner-medullary osmolality; ADH upregulates UT-A1/A3; low protein lowers max U_osm.
7. ADH → V2 → Gs → cAMP → PKA → AQP2 apical insertion in collecting duct principal cells.
8. AQP2 = regulated/apical; AQP3 & AQP4 = constitutive/basolateral exit.
9. Central DI responds to DDAVP; nephrogenic DI does not (lithium, hypercalcaemia, hypokalaemia).
10. SIADH = euvolaemic hyponatraemia, U_osm >100, urine Na >30–40, low uric acid; treat with fluid restriction ± tolvaptan.
11. Correct hyponatraemia ≤8–10 mmol/L/24 h → avoid osmotic demyelination (central pontine myelinolysis).
12. C_H2O = V − C_osm: positive in water diuresis (no ADH), negative when concentrating (max ADH).